

# Alberto Picca

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1344623/publications.pdf>

Version: 2024-02-01

15  
papers

245  
citations

1478505

6  
h-index

1199594

12  
g-index

15  
all docs

15  
docs citations

15  
times ranked

411  
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience. <i>Neurological Sciences</i> , 2022, 43, 2031-2041.	1.9	16
2	Progressive multifocal leukoencephalopathy after first-line radiotherapy and temozolomide for glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 497-498.	1.2	2
3	Neurological complications of immunotherapy and monoclonal antibody therapy. , 2022, , 521-536.		0
4	Innovating Strategies and Tailored Approaches in Neuro-Oncology. <i>Cancers</i> , 2022, 14, 1124.	3.7	3
5	Adult brainstem glioma: a multicentre retrospective analysis of 47 Italian patients. <i>Neurological Sciences</i> , 2021, 42, 1879-1886.	1.9	5
6	Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice. <i>Current Opinion in Oncology</i> , 2020, 32, 603-612.	2.4	5
7	Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions. <i>Neuro-Oncology</i> , 2020, 22, 1614-1624.	1.2	41
8	Current therapeutic approaches to diffuse grade II and III gliomas. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628561775203.	3.5	35
9	Diffuse gliomas with <i>FGFR3</i> â€TACC3 fusion have characteristic histopathological and molecular features. <i>Brain Pathology</i> , 2018, 28, 674-683.	4.1	48
10	Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas. <i>Current Opinion in Neurology</i> , 2018, 31, 727-732.	3.6	6
11	The clinical use of IDH1 and IDH2 mutations in gliomas. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 1041-1051.	3.1	34
12	<i>FGFR1</i> actionable mutations, molecular specificities, and outcome of adult midline gliomas. <i>Neurology</i> , 2018, 90, e2086-e2094.	1.1	47
13	Actionable targets involving FGF receptors in gliomas: Molecular specificities, spatial distribution, clinical outcome and radiological phenotype.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2005-2005.	1.6	3
14	PATH-12. CLINICAL, MOLECULAR AND RADIOLOGICAL FEATURES OF FGFR-TACC POSITIVE GLIOMAS. <i>Neuro-Oncology</i> , 2017, 19, vi173-vi173.	1.2	0
15	Targeting glioblastoma stem-cells: a recurrent challenge in neuro-oncology. <i>Translational Cancer Research</i> , 2017, 6, S1197-S1199.	1.0	0